LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...
Credit: Fresenius Kabi. Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion. The biosimilar received FDA approval on ...
The MarketWatch News Department was not involved in the creation of this content. -- Tyenne(R) is the first tocilizumab biosimilar available with both an intravenous and subcutaneous formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results